Can Menelat (Mirtazapine) Cause Parkinsonism?
Yes, mirtazapine can cause drug-induced parkinsonism, though it is rare. Based on the available evidence, mirtazapine has been documented to cause parkinsonian symptoms in 2 reported cases out of 179 movement disorder cases associated with this medication 1.
Understanding the Risk
Mirtazapine is an atypical antidepressant that works through antagonism of alpha-2, H1, 5-HT2A, 5-HT2C, and 5-HT3 receptors 1. Unlike typical antipsychotics that directly block dopamine receptors (the primary mechanism of drug-induced parkinsonism), mirtazapine's mechanism makes parkinsonian side effects uncommon but still possible.
Clinical Profile of Mirtazapine-Associated Movement Disorders
From a comprehensive literature review of 179 cases across 20 countries 1:
- Onset timing: Average 7.54 days after starting mirtazapine
- Recovery: 82.60% of patients improved within one week of management
- Most common movement disorders: Restless legs syndrome (69 cases), tremors (35 cases), akathisia (10 cases)
- Parkinsonism: Only 2 documented cases
- Patient demographics: Mean age 57 years, 60% female
Key Distinguishing Features
When evaluating parkinsonian symptoms in a patient taking mirtazapine, consider:
- Timing: Symptoms typically appear within the first 1-2 weeks of treatment 1
- Reversibility: Drug-induced parkinsonism from mirtazapine should improve within one week of discontinuation 1
- Other movement disorders: More likely to see restless legs syndrome, tremor, or akathisia than true parkinsonism
Management Algorithm
If parkinsonian symptoms develop on mirtazapine:
- Discontinue mirtazapine immediately - This is the primary management strategy 1
- Do not rechallenge with mirtazapine if symptoms occurred 1
- Monitor for improvement - Expect resolution within one week in most cases
- Consider alternative diagnosis if symptoms persist beyond 6-12 months, as this suggests underlying Parkinson's disease rather than drug-induced parkinsonism 2, 3
Important Caveats
- Prophylactic anticholinergics are NOT indicated for mirtazapine-associated movement disorders 3
- Unlike akathisia from mirtazapine (where benzodiazepines may help), parkinsonism requires drug discontinuation 1
- If symptoms persist beyond expected recovery time, consider dopamine transporter (DaT) scan imaging to differentiate drug-induced parkinsonism from underlying Parkinson's disease 4, 3
Clinical Context
While mirtazapine is generally well-tolerated and listed among preferred antidepressants with favorable adverse effect profiles 5, movement disorders can occur. The medication is particularly useful for patients with depression, insomnia, and poor appetite 6, 7, but clinicians must remain vigilant for neurological side effects.
The risk of parkinsonism with mirtazapine is substantially lower than with dopamine receptor-blocking agents (antipsychotics, metoclopramide), which cause drug-induced parkinsonism in approximately 15-25% of cases 4, 2. However, any new parkinsonian symptoms in a patient taking mirtazapine warrant immediate medication review and discontinuation.